Multiple Sclerosis Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, unpredictable disease that leads to the loss of information exchange in the brain and between the brain and body. MS affects the central nervous system principally spinal cord, optic nerves, and the brain. In Multiple Sclerosis, damaging of insulating covers of nerve cells by demyelinating of these covers in the brain and spinal cord.

In MS, symptoms are like numbness, tingling, dizziness and fatigue, sexual dysfunction, muscle weakness, ataxia, acute or chronic pain, change in sensation, vision problems, tremor, memory problems, and muscle spasms. Signs and symptoms may vary in MS and it depends on the level of the damage to nerve cells.

Multiple Sclerosis is an autoimmune disorder, in which the immune system attacks the myelin sheath which protects the nerve cells leads to communication problems in the body. The main cause behind this is not yet found. But it is believed that it is a result of accumulated genetic and environmental factors. Some cause may be genetic, geographical, infection, and acquired factors as well.

Multiple Sclerosis has no cure. Medication helps to prevent new attacks or to stabilize functioning after an attack.

Sub-tracks:

Primary progressive MS
Relapse-remitting MS (RRMS)
Secondary progressive MS (SPMS)
Clinically isolated syndrome (CIS)
Multiple Sclerosis Treatment and Management
Multiple Sclerosis case reports

Market Analysis: The Multiple Sclerosis (MS) market is expected to grow steadily between 2025 and 2030, with a CAGR ranging from 3.2% to 10.06%. The global MS therapeutics market could reach USD 29–39 billion by 2030, driven by rising prevalence and advancements in treatment options. The Primary Progressive MS segment is showing notable momentum with a projected 14.8% CAGR. Regional growth, particularly in India and the Asia-Pacific, is supported by active R&D in disease-modifying therapies, including new oral and innovative drug classes.

Tracks